Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dimensional World ex U.S. Core Equity 2 ETF (NY:DFAX)

36.56 -0.44 (-1.18%)
Delayed Quote Updated: 2:41 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dimensional World ex U.S. Core Equity 2 ETF

< Previous 1 2 3 Next >
News headline image
Shell Stock Hits 52-Week High – Here’s Why ↗
Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 
Via Stocktwits
News headline image
TrueWealth Financial Buys $12 Million of First Trust Managed Municipal ETF ↗
This municipal bond ETF delivers tax-exempt income through a diversified portfolio of federally tax-free debt securities. 
Via The Motley Fool
Topics Bonds ETFs Regulatory Compliance
News headline image
LRI Investments Buys $16 Million of Vanguard 0-3 Month Treasury Bill ETF ↗
This ETF tracks short-term U.S. Treasury bills, offering investors a liquid, low-risk vehicle for short-duration capital allocation. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week ↗
Via Stocktwits
BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’ ↗
Via Stocktwits
Stellantis Stock Drops As It Reportedly Scraps Jeep and Chrysler Plug-In Hybrid Vehicles In US ↗
Via Stocktwits
Tilray Stock On Track For Near 2-Month High As 'Weednesday' Buzz Builds Around Trump Cannabis Order — Retail Eyes Massive Upside ↗
Via Stocktwits
Topics Cannabis Government
News headline image
Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025 ↗
The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg. 
Via Stocktwits
News headline image
Novo Nordisk Shares Tumble On Q4 Miss, Weak Sales Forecast And Competition Concerns ↗
The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%. 
Via Stocktwits
News headline image
Why Bitfarms Stock Is Down After Hours? ↗
Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic ↗
Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration. 
Via Stocktwits
News headline image
NVS Stock Rises After FDA Grants Breakthrough Therapy Designation For Autoimmune Disorder Treatment ↗
Novartis looks to submit data from its many trials of Ianalumab with health authorities starting in early 2026 for potential approval. 
Via Stocktwits
Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study ↗
Via Stocktwits
BABA Stock Rises Pre-Market As AI-Driven Cloud Growth Drives Revenue Beat ↗
Via Stocktwits
News headline image
Stellantis CEO Says New Engine, Vehicle Models Will Drive ‘Progressively Better’ Demand ↗
Filosa said that the company is on track on its full year guidance through the end of November. 
Via Stocktwits
Topics Government World Trade
News headline image
Li Auto Posts Unexpected Loss In Q3 As EV Sales Drop ↗
CEO Xiang Li highlighted challenges pertaining to the supply chain and product lifecycle, among others. 
Via Stocktwits
Topics Economy
News headline image
Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies ↗
The company said that it is discontinuing the trials. 
Via Stocktwits
Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic ↗
Via Stocktwits
Takeda Pharmaceuticals’ Genetic Disease Therapy Under FDA Probe After Pediatric Patient Dies ↗
The death of a pediatric congenital thrombotic thrombocytopenic purpura patient appears to be related to Adzynma, the FDA said. 
Via Stocktwits
Toyota Commits Up To $10B Additional Investments In US Over Five Years ↗
Via Stocktwits
Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence ↗
Via Stocktwits
AstraZeneca Announces $4.5B Investment In Virginia ↗
Via Stocktwits
AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure ↗
Via Stocktwits
News headline image
Novo Nordisk Brings Back Former CEO To Lead Board ↗
Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 
Via Stocktwits
News headline image
Stellantis NV Recalls Over 320,000 Jeep Plug-In Hybrids In US Over Fire Risk ↗
The recall includes certain model year 2020- 2025 Jeep Wrangler 4Xe and model year 2022-2026 Grand Cherokee 4Xe plug-in hybrid vehicles. 
Via Stocktwits
Topics Product Recall
News headline image
Alibaba’s AI Glasses To Be Priced At $659, Pre-Sale On October 24 On Its E-commerce Platform Tmall: Report ↗
According to a CNBC report, the price of the product, known as Quark AI Glasses, during pre-sale would be 4,699 yuan. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug ↗
The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 
Via Stocktwits
US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles ↗
Via Stocktwits
US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ ↗
Via Stocktwits
Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-stage Study ↗
Via Stocktwits
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.